Baseline neutrophil-to-lymphocyte ratio as a predictive and prognostic biomarker in patients with metastatic castration-resistant prostate cancer treated with cabazitaxel versus abiraterone or enzalutamide in the CARD study
在CARD研究中，基线中性粒细胞与淋巴细胞比值作为预测和预后生物标志物，用于评估接受卡巴他赛治疗的转移性去势抵抗性前列腺癌患者与接受阿比特龙或恩扎卢胺治疗患者的疗效。
期刊:ESMO Open
影响因子:8.3
doi:10.1016/j.esmoop.2021.100241
de Wit, R; Wülfing, C; Castellano, D; Kramer, G; Eymard, J-C; Sternberg, C N; Fizazi, K; Tombal, B; Bamias, A; Carles, J; Iacovelli, R; Melichar, B; Sverrisdóttir, Á; Theodore, C; Feyerabend, S; Helissey, C; Foster, M C; Ozatilgan, A; Geffriaud-Ricouard, C; de Bono, J
